Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by palinc2000on Feb 22, 2024 2:14pm
129 Views
Post# 35893901

RE:Today's Call

RE:Today's Call

They said they were pleased with the results so far (or something like that) and they will no longer make comments such as @exceeding expectations!!
Which also means I think that they will not disclose in future PR s  if NOT meeting expectations
 

TechOne wrote: I did not listen to it so what I have summarized from posts here so please tell me know I got it.. Or not.. 

1.  Baxter made the extension deal and paid the 2nd milestone, CAD $ 2M without looking at the intrim data.

2.  Baxter will wait till they get the numbers when the trial is completed. Does not want data leak or any issue with FDA regarding the trial..

3.  Spectral still needs $17-18 M to take the trial to conclusion etc. etc. 

So hence, no firework in POS and we are still on the same trajectory of slow burn for next few months until it is all done.. 

Does that cover it or did I miss something..  Thanks.. 

 

<< Previous
Bullboard Posts
Next >>